ClinicalTrials.gg
RecruitingNCT07177885TRP-TriptansUpdated Mar 9, 2026

Tryptophan as a Modulating Factor in the Antimigraine Efficacy of Triptans

An observational study in Migraine, sponsored by University Hospital, Clermont-Ferrand. Recruiting at 1 site in France. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-03-09.

Sponsored by University Hospital, Clermont-Ferrand · Observational

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
144
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 71 studies in Migraine Disorders with a site in France — 14 open to participants now, 20 under way, 6 of them phase 3. Migraine Disorders · France.

Planned enrollment
11th of 20
144 · median 155
Started
2026
with 4 others
Observational
20 of 71
4 open now
Primary completion
2028-03
later than 13 of 19 live
Registered
68th of 71
by date
Lead sponsor
9 of 71
University Hospital, Clermont-Ferrand

Among the 71 studies in Migraine Disorders with a site in France, this one is the 11th largest by planned enrollment of the 20 observational ones that give a count, is one of 5 that started in 2026, is one of 20 observational ones, reaches primary completion later than 13 of the 19 other live ones, and was the 68th registered.

Migraine Disorders

1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

14 of the 71 studies in Migraine Disorders with a site in France are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies in Migraine Disorders with a site in France, or all of them as a file.
02

Study summary

Migraine is a leading cause of disability, and while triptans are commonly used to treat migraine attacks, over 20% of patients don't respond well to them. This study aims to understand why some people don't benefit from triptans. One key focus is tryptophan, an amino acid that plays a role in migraine and is involved in producing serotonin, which affects pain and inflammation. The study will compare levels of tryptophan and its by-products in patients who respond well to triptans versus those who don't. It will also look at how conditions like inflammatory bowel disease may affect tryptophan absorption. The goal is to improve migraine treatments tailored to different patient needs, though participants may not experience immediate personal benefits.

Read the detailed description

Migraine is a leading cause of disability worldwide. Triptans are medications used to treat migraine attacks. They work mainly in two ways: by narrowing the blood vessels in the brain and by stopping the release of substances that cause pain and inflammation. Triptans help relieve migraine pain and other symptoms, like digestive problems, light sensitivity, and disability during an attack. However, more than 20% of patients do not respond well to these medications, and the reasons for this are not well understood.

Tryptophan is an essential amino acid, which means it must come from food because the body cannot produce it. Tryptophan plays an important role in migraines, especially through its by-products, such as serotonin and kynurenine. Research has shown that problems with tryptophan metabolism can make migraines worse, along with other sensory symptoms.

Although no study has directly linked tryptophan to the effectiveness of triptans, the investigators found in a preclinical study that a low-tryptophan diet could reduce the effectiveness of sumatriptan, one of the most commonly used triptans. A deficiency in tryptophan can occur when the body has trouble absorbing it from the intestines. Conditions like inflammatory bowel diseases (such as irritable bowel syndrome or Crohn's disease) or diabetes can affect this absorption, which might reduce the body's ability to process tryptophan.

This study aims to better understand how tryptophan might affect resistance to triptans in migraine patients. The investigators will compare blood levels of tryptophan and its by-products in patients who respond well to triptans versus those who do not. If participants are having a lumbar puncture as part of their regular check-up, the investigators will also examine these substances in the cerebrospinal fluid. Additionally, the investigators will explore any connection between tryptophan metabolism and inflammatory bowel disease.

03

Conditions studied

  • Migraine

Browse trials for

Keywords

  • Triptan
  • Tryptophan
  • inflammatory diseases
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Participants in the study will be recruited from the following centers:

  • Centre 01: CHU de Clermont-Ferrand, Gabriel Montpied site, located at 58 Rue Montalembert, 63000 Clermont-Ferrand, France.
  • Centre 02: Headache Emergency Center, Hôpital Lariboisière, located at 2 Rue Ambroise Paré, 75010 Paris, France.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Cisgender women, premenopausal, aged 18 to 50 years.
  • Cisgender men, aged 18 to 50 years.
  • Diagnosed with migraine (according to ICHD-3 criteria).
  • Diagnosed as responders or non-responders to triptans (according to the criteria of Sacco et al., 2022).
  • Permitted comparison groups include: triptans used alone or in combination with other migraine treatments (e.g., NSAIDs, acetaminophen, ergotamine, opioids, antiemetics).
  • All routes of administration and all dosages.
  • Affiliation with a social security system.

Exclusion criteria

Exclusion Criteria:

  • Patients under guardianship, curatorship, deprivation of liberty, or legal protection
  • Pregnant and breastfeeding women
05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
144 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Migraineurs responding to triptans

    Blood collection

    Biological: Blood collection

  • Migraine sufferers resistant to triptans

    Blood collection

    Biological: Blood collection

Interventions

  • BiologicalBlood collection

    Blood sampling. For patients who have had their cerebrospinal fluid sample taken as part of their treatment, a surplus sample will be used to perform the same measurements.

06

What researchers measure

Primary outcomes

  1. Plasma tryptophan levels

    Variation in plasma tryptophan levels between triptan-resistant and triptan-responsive migraine patients.

    Time frame: Baseline

Secondary outcomes

  1. Serotonin levels

    Variation in plasma serotonin levels between triptan-resistant and triptan-responsive migraine patients.

    Time frame: Baseline

  2. Kynurenine levels

    Variation in plasma kynurenine levels between triptan-resistant and triptan-responsive migraine patients.

    Time frame: Baseline

  3. Levels of neutral amino acids

    Variation in plasma levels of neutral amino acids between triptan-resistant and triptan-responsive migraine patients.

    Time frame: Baseline

  4. Levels of cytokines (IL-6, IL-10, IL-1α, IL-1β)

    Variation in plasma levels of cytokines (IL-6, IL-10, IL-1α, IL-1β) between triptan-resistant and triptan-responsive migraine patients.

    Time frame: Baseline

  5. Dietary tryptophan intake

    Dietary tryptophan intake via a self-questionnaire on eating habits

    Time frame: Baseline

  6. Inflammatory bowel disorders

    Presence/absence of inflammatory bowel disorders

    Time frame: Baseline

  7. Blood nutritional biomarkers

    Variation in blood nutritional biomarkers (glycemia, cholesterol)

    Time frame: Baseline

Other outcomes

  1. Hospital Anxiety and Depression Scale

    Tool for assessing levels of anxiety and depression in patients

    Time frame: Baseline

  2. Headache Impact

    The HIT-6 will be used to assess the impact of headaches on a person's daily life

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Mar 2028, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2025
First posted
Sep 17, 2025
StartActual
Mar 5, 2026
Primary completionEst.
Mar 2028
CompletionEst.
Mar 2028
Last update
Mar 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07177885
Collaborators
University of the Basque Country (UPV/EHU), Hopital Lariboisière
Responsible party
Sponsor
First posted
Sep 17, 2025
Start date
Mar 5, 2026
Primary completion
Mar 2028 (estimated)
Completion
Mar 2028 (estimated)
Last update
Mar 9, 2026

Study contacts

Lise Laclautre
Contact
promo_interne_drci@chu-clermontferrand.fr
0033473754027
Xavier Moisset
principal investigator · University Hospital, Clermont-Ferrand
Cristina Alba-Delgado
principal investigator · Université d'Auvergne

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion